Bausch Health Companies BHC Salix — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bausch Health Companies's salix — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bausch Health Companies's salix — R&D?
- Bausch Health Companies (BHC) reported salix — R&D of $19M in Q1 2026.
- How has Bausch Health Companies's salix — R&D changed year-over-year?
- Bausch Health Companies's salix — R&D increased by 11.8% year-over-year, from $17M to $19M.
- What is the long-term trend for Bausch Health Companies's salix — R&D?
- Over 3 years (2022 to 2025), Bausch Health Companies's salix — R&D has grown at a 16.5% compound annual growth rate (CAGR), from $50M to $79M.
- What does salix — R&D mean?
- Captures the investment in scientific research, clinical trials, and product development specifically aimed at expanding or maintaining the Salix segment's product pipeline. This metric reflects the company's commitment to long-term innovation and future growth within its specialized therapeutic areas. High investment levels indicate a focus on sustaining a competitive advantage through new product launches.